research involving persons at risk for impaired decisionmaking donald l. rosenstein, m.d. national...
TRANSCRIPT
![Page 1: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/1.jpg)
Research Involving Persons at Risk for Impaired Decisionmaking
Donald L. Rosenstein, M.D.National Institutes of Health
![Page 2: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/2.jpg)
Overview
• Dimensional issues and categorical decisions
• A recent case: the ARDS Network Trial
• An IRB approach to protocols involving subjects at risk for impaired decisionmaking capacity (DMC)
• Informed consent monitoring and Independent capacity assessment (ICA)
• Advance directives for research
![Page 3: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/3.jpg)
Competing or Integrated Agendas?
Science Medicine
Clinical ResearchResearch differs fundamentally from medical care
in its purpose, methods, and justification of risks
![Page 4: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/4.jpg)
Spectrum of Clinical Research
Healthy Control
“Non-therapeutic” study
Payment
Severely Ill Patient
Clinical trial
No payment
![Page 5: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/5.jpg)
The Acute Respiratory Distress Syndrome Network Trial
• Multi-center (10 university centers), randomized trial of mechanical ventilation in patients with acute lung injury and ARDS
NEJM 2000; 342:1301-8
![Page 6: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/6.jpg)
NHLBI ARDS Network
• Cleveland Clinic Foundation
• Denver Health Medical Center
• Duke University
• Johns Hopkins University
• UCSF
• University of Colorado
• University of Maryland
• University of Utah
• University of Pennsylvania
• University of Washington
• Vanderbilt University
• Massachusetts General Hospital
• University of Michigan
• Jefferson University
![Page 7: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/7.jpg)
The Acute Respiratory Distress Syndrome Network Trial
• Multi-center (10 university centers), randomized trial of mechanical ventilation in patients with acute lung injury and ARDS
• Comparison of lower tidal volumes with “traditional” tidal volumes
NEJM 2000; 342:1301-8
![Page 8: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/8.jpg)
The Acute Respiratory Distress Syndrome Network Trial
• Multi-center (10 university centers), randomized trial of mechanical ventilation in patients with acute lung injury and ARDS
• Comparison of lower tidal volumes with “traditional” tidal volumes
• Eligibility : intubated and mechanically ventilated
– Manuscript stated “informed consent was obtained from the patients or surrogates at all but one hospital where this requirement was waived.”
NEJM 2000; 342:1301-8
![Page 9: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/9.jpg)
The Acute Respiratory Distress Syndrome Network Trial
• Multicenter (10 university centers), randomized trial of mechanical ventilation in patients with acute lung injury and ARDS
• Comparison of lower tidal volumes with “traditional” (higher) tidal volumes
• Eligibility : intubated and mechanically ventilated
• Death was primary outcome measure
NEJM 2000; 342:1301-8
![Page 10: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/10.jpg)
The Acute Respiratory Distress Syndrome Network Trial
• Multicenter (10 university centers), randomized trial of mechanical ventilation in patients with acute lung injury and ARDS
• Comparison of lower tidal volumes with “traditional” (higher) tidal volumes
• Eligibility : intubated and mechanically ventilated
• Death was primary outcome measure
• Lower mortality observed in lower tidal volume group
NEJM 2000; 342:1301-8
![Page 11: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/11.jpg)
Department of Health and Human Services (HHS)
HHS
Office of the Secretary
NIH OHRP
IRP ERP (OPRR)
![Page 12: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/12.jpg)
OHRP Findings and Concerns
• Failure of IRB Review process
– Waiver of consent
– Inadequate informed consent documents
• Failure to obtain “legally effective informed consent of the subject or the subject’s legally authorized representative”
– Inconsistencies with regard to state law allowing surrogate permission
![Page 13: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/13.jpg)
OHRP Findings and Concerns
“ OHRP is concerned that (a) both the subjects, because of their impaired mental state, and the subjects’ family members, because of the psychological stress of having a critically ill family member being treated in an intensive care unit, appear likely to have been vulnerable to coercion or undue influence; and (b) the IRB failed to insure that there were additional safeguards included in the study to protect the rights and welfare of these vulnerable subjects.”
OHRP Determination letter, 2/7/02
![Page 14: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/14.jpg)
45 CFR 46.111 Criteria for IRB Approval of Research
(b) When some or all of the subjects are likely to be vulnerable to coercion or undue influence, such as children, prisoners,
pregnant women, mentally disabled persons, or economically or educationally
disadvantaged persons, additional safeguards have been included in the study to protect the
rights and welfare of these subjects.
![Page 15: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/15.jpg)
Central Questions
1. Who is vulnerable because of a mental disability?
2. What are the appropriate additional safeguards for vulnerable subjects?
3. How can these safeguards be optimally implemented ?
![Page 16: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/16.jpg)
Defining the Scope of Impaired Decisionmaking Capacity
• Imprecise language
• competency, capacity, and consent
• cognitive impairment does not necessarily mean decisional incapacity
• mental disability, psychiatric illness/disorder, and vulnerability
“capacity to give informed consent for this study”
![Page 17: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/17.jpg)
Research With Impaired or Potentially Impaired Subjects
• Medication trial for Alzheimer’s Disease
• ECT trial for delusional depression
• Placebo-controlled study in acute mania
• MRS study of a delirium model
• Establishing cell lines for genetics studies of mental retardation
• Tryptophan depletion in autism (adults)
• Medication-free studies of schizophrenia
![Page 18: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/18.jpg)
The Most Contentious Case
Research
with subjects who
can not provide informed consent
that offers
no prospect of direct medical benefit
and involves
more than minimal risk
![Page 19: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/19.jpg)
The Nuremberg Code
The voluntary consent of the human subject is absolutely essential.
1946
![Page 20: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/20.jpg)
Central Tension
The need for improved diagnosis and treatment through research.
versus
The danger of exploiting vulnerable individuals.
![Page 21: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/21.jpg)
Ethically
problematic unethical
![Page 22: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/22.jpg)
Questions for the IRB
• Can the scientific question be answered with capacitated subjects?
• What are the relevant risks and benefits?
![Page 23: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/23.jpg)
risks benefits
Institutional Review Board
•minimal risk
•minor increment over minimal risk (children)
•greater than minimal risk
•direct benefit to the subject
•benefit to society
•(indirect benefits to subject)
![Page 24: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/24.jpg)
Questions for the IRB
• Can the scientific question be answered with capacitated subjects?
• What are the relevant risks and benefits?
• What is the nature of the anticipated decisionmaking impairment?
![Page 25: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/25.jpg)
Factors Influencing Decisionmaking Capacity
• Memory, attention, concentration
• Conceptual organization
• Psychosis and hallucinations
• “Executive” function
• Risk assessment
• Mood
• Intuition
• Insight
• Behavior
• Duty and altruism
• “Relatedness”
![Page 26: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/26.jpg)
Will Subjects Be Able to Provide Informed Consent?
• Subjects who are currently unable to provide informed consent
• Subjects who will become unable to provide informed consent
• Subjects who are at increased risk of becoming unable to provide informed consent
![Page 27: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/27.jpg)
Questions for the IRB
• Can the scientific question be answered with capacitated subjects?
• What are the relevant risks and benefits?
• What is the nature of the anticipated decisionmaking impairment?
• Are adequate safeguards in place?
![Page 28: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/28.jpg)
Additional Protections
• Clinical monitoring of ongoing research
• Data and safety monitoring boards
• Ethics consultation
![Page 29: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/29.jpg)
Additional Protections
• Clinical monitoring of ongoing research
• Data and safety monitoring boards
• Ethics consultation
• Informed consent monitoring
• Independent capacity assessment
![Page 30: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/30.jpg)
Consent Monitoring and Independent Capacity Assessment
Disclosure and voluntary participation
Mastery of specific study
Basic understanding of clinical research
![Page 31: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/31.jpg)
Decisionmaking Capacity
Unable to make decisions
Fully capacitated
Able to assign a substitute
decisionmaker
Appreciates the differences between
clinical care and clinical research
Able to make medical decisions
![Page 32: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/32.jpg)
National Bioethics Advisory Commission (NBAC) Report
“Research Involving Subjects at Risk for
Impaired Decisionmaking Capacity” 1998
![Page 33: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/33.jpg)
National Bioethics Advisory Commission (NBAC) Report
• Recommendation #8: “For research protocols that present greater than minimal risk, an IRB should require that an independent, qualified professional assess the potential subject’s capacity to consent…”
“Research Involving Subjects at Risk for
Impaired Decisionmaking Capacity” 1998
![Page 34: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/34.jpg)
Triggers for Capacity Assessment
• Concern about a class of prospective subjects
• Protocol designed to enroll “at-risk” subjects
• Protocol that may precipitate loss of decisional capacity
![Page 35: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/35.jpg)
Triggers for Capacity Assessment
• Concern about a class of prospective subjects
• Protocol designed to enroll “at-risk” subjects
• Protocol that may precipitate loss of decisional capacity
• Concern about an individual
• Prior to or at the time of enrollment
• During study participation
![Page 36: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/36.jpg)
Assessment of Decisionmaking Capacity (DMC)
• Presumption of capacity/competence
• Medical aspects of assessment of DMC
– Dehydration, medication toxicity, sickness, delirium, psychosis, severe depression, grief, mania
![Page 37: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/37.jpg)
Capacity to Give Informed Consent for Research
Does this individual have a medical, neurological or psychiatric disorder that compromises his or her capacity to understand, appreciate and reason with respect to the details of a given study?
Clinical judgment
Can this person give informed consent and should they be enrolled into the study?
Ethical judgment
![Page 38: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/38.jpg)
Assessment of Decisionmaking Capacity (DMC)
• Presumption of capacity/competence
• Medical aspects of assessment of DMC
– Dehydration, medication toxicity, sickness, delirium, psychosis, severe depression, grief, mania
• Who does this?
• How is it done?
![Page 39: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/39.jpg)
UNDERSTANDING
purpose of study; what tests and procedures
major risks, discomforts and possible benefits
APPRECIATION
is the main purpose to benefit you?
differences between this study and regular care
REASONING
if you decline, what will you do instead?
whose decision, can you stop participating?
CHOICE
MacArthur Competence Assessment Tool (MacCAT-CR)
![Page 40: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/40.jpg)
Assessment of Decisionmaking Capacity
Business as usual
NBAC: mandated, formal ICA
Clinical judgment of investigator
McCAT-CR for each protocol
NIMH IRP
CORE
Independent, semi-structured
interview based on McCAT-CR
![Page 41: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/41.jpg)
Additional Protections
• Clinical monitoring of ongoing research
• Data and safety monitoring boards
• Ethics consultation
• Informed consent monitoring
• Independent capacity assessment
• Advance directives and legally authorized representatives (e.g., guardianship, DPA)
![Page 42: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/42.jpg)
NIH Advance Directive for Health Care and Medical Research Participation
I. Durable Power of Attorney
II. Advance Directive for Health Care
III. Advance Directive for Research Participation
![Page 43: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/43.jpg)
NIH Advance Directive for Health Care and Medical Research Participation
If I lose the ability to make my own decisions, I do not want to participate in any medical research.
If I lose…I am willing to participate in medical research that might help me.
If…won’t help me but might help others as long as it involves no more than minimal risk of harm to me.
If…that won’t help me but might help others even if it involves greater than minimal risk of harm to me.
![Page 44: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/44.jpg)
Summary and Recommendations
• Is it necessary to enroll vulnerable subjects?
• Decisional capacity with respect to providing informed consent for a specific study
• Subject vulnerability, research risks and benefits:
• Determined by local IRB
• Defined by study population and specific protocol rather than by diagnosis alone
![Page 45: Research Involving Persons at Risk for Impaired Decisionmaking Donald L. Rosenstein, M.D. National Institutes of Health](https://reader036.vdocuments.mx/reader036/viewer/2022062719/56649ec45503460f94bcf137/html5/thumbnails/45.jpg)
Summary and Recommendations (Cont.)
• Investigators should describe in detail:
• methods of assessing decisional capacity
• procedures for informed consent or proxy consent
• provision of adequate safeguards
• IRBs should promote increased use of:
• independent capacity assessment
• consent monitors
• legally authorized representatives
• research advance directives
• IRB discretion regarding intermediate risk